DNActive, which specialises in the development of genetic tests and the manufacture of products based on the genetics of patients, has recently received a round of funding. Its investor has been the crowdfunding platform SociosInversores.com, which has injected 372,500 euros.
Following this analysis, we have decided to investigate the biotechnology sector with the sale of companies most prominent in 2019.
Founded in 2016 and based in Granada, DNActive Genetic Analysis is a bio-health company specialising in developing genetic tests and subsequently manufacture tailor-made products based on the genetic characteristics of the individual. After this process, they market disease prevention plans, nutritional itineraries, adapted training, customised supplementation or cosmetics, among others. As distribution channels for these products they use clinics and laboratories, pharmacies and their own website.
DNActive's operating income in 2017 was €69,801 and in the first half of 2018 it doubled, 150,221 euros. Moreover, in early 2018, they were awarded a Horizon 2020 grant of 46,000 euros.
On 6 March 2019, it closed a round of financing via crowdfunding for an amount of 372,500 euros. Its investor has been the crowdfunding platform PartnersInvestors.com.
Curiosamente, toda la semilla va a ir a parar al Marketing de la empresa DNActive. La inversión se divide en Media, face-to-face and national promotional marketing and within them, newsletter campaigns, sponsorships or merchandising, among others, will be carried out.
You can check all the detailed information about the operation on this page of SociosInversores.com.
Después de ver DNActive, a continuación vamos a repasamos las operaciones de sale of companies que se han confirmado ya en el sector de la biotecnología en el 2019. También puedes echar un vistazo a un estudio que realizamos posteriormente sobre las rondas que se estaban confirmando en 2018 en esta entrada.
The most significant sales transactions in 2019 are as follows:
MyoScience is dedicated to development and commercialisation of dermatological technology products. It was founded in 2005 and is based in Redwood City, California.
On 5 March, we learned of the sale agreement between MyoScience and Pacira Pharmaceuticals. Under the terms of the agreement, Pacira will pay up to $220 million in total, being 120 in cash upfront and an additional 100 on reaching targets. The sale is expected to close in early April 2019.
Founded in 2005, MolecularMD Corporation develops and markets specialised molecular diagnostics for oncology applications. Its tests are designed to enable the selection, monitoring and management of patients treated with molecularly targeted cancer therapies.
ICONa provider of outsourced drug development services, acquired MolecularMD on 21 February. The amount of the deal has not been disclosed.
Auris Health (San Carlos, California) is dedicated to the development of robotic technology for medical applications. The company designs a novel dual-arm microsurgical system for ophthalmic surgery. The company is committed to transforming medical intervention by integrating robotics, micro instrumentation, endoscope design, sensing and data science into one platform.
On 13 February, we learned of the sale of the company to Jhonson & Jhonson. The amount of the operation reached the astonishing figure of $3.4B.
We found this company curious. Taconic Biosciences for more than 6 decades has been a provider of research models and supporting the efforts of the research community to reduce the use of animals. Through dedicated teams of scientific and project management professionals, they work with clients to design and execute project plans to meet their research objectives.
The global private equity and alternative asset investment firm H.I.G. Capital executed leveraged buyout of Taconic on 7 February. The amount of the transaction has not been disclosed.
Founded in 2000, Labcyte is a laboratory with an innovative approach to dispense small volumes of liquids for life science applications. It is known for its Echo® acoustic droplet ejection technology, which uses sound waves to transfer small amounts of liquid with unrivalled speed and precision.
This innovation has led to the sale of the company to Beckman Coulter Life Sciences. The transaction took place on 30 January and the amount was not confirmed.